Profile data is unavailable for this security.
About the company
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
- Revenue in USD (TTM)0.00
- Net income in USD-67.68m
- Incorporated2017
- Employees101.00
- LocationCabaletta Bio Inc2929 Arch Street, Suite 600PHILADELPHIA 19104United StatesUSA
- Phone+1 (267) 759-3100
- Fax+1 (302) 655-5049
- Websitehttps://www.cabalettabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GH Research PLC | 0.00 | -35.59m | 576.47m | 49.00 | -- | 2.63 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
| Novavax Inc | 983.71m | -545.06m | 580.81m | 1.54k | -- | -- | -- | 0.5904 | -5.53 | -5.53 | 9.42 | -5.14 | 0.485 | 8.76 | 5.18 | 637,527.60 | -26.88 | -46.06 | -- | -269.57 | 65.10 | -- | -55.41 | -75.94 | 0.6741 | -38.31 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Korro Bio Inc | 0.00 | -81.17m | 584.09m | 101.00 | -- | 2.97 | -- | -- | -68.38 | -68.38 | 0.00 | 21.20 | 0.00 | -- | -- | 0.00 | -47.34 | -31.55 | -53.69 | -36.48 | -- | -- | -- | -365.87 | -- | -- | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Lyell Immunopharma Inc | 130.00k | -234.63m | 584.42m | 224.00 | -- | 0.8918 | -- | 4,495.55 | -0.9353 | -0.9353 | 0.0005 | 2.58 | 0.0002 | -- | -- | 580.36 | -27.81 | -- | -29.04 | -- | -- | -- | -180,486.20 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Savara Inc | 0.00 | -54.70m | 585.75m | 37.00 | -- | 4.17 | -- | -- | -0.3424 | -0.3424 | 0.00 | 1.02 | 0.00 | -- | -- | 0.00 | -34.47 | -36.86 | -36.36 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.158 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Aerovate Therapeutics Inc | 0.00 | -75.52m | 590.69m | 51.00 | -- | 5.38 | -- | -- | -2.87 | -2.87 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -57.49 | -- | -63.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| Mind Medicine (MindMed) Inc | 0.00 | -95.73m | 594.47m | 57.00 | -- | 4.45 | -- | -- | -2.45 | -2.45 | 0.00 | 1.90 | 0.00 | -- | -- | 0.00 | -65.01 | -- | -78.34 | -- | -- | -- | -- | -- | -- | -- | 0.1531 | -- | -- | -- | -68.55 | -- | -- | -- |
| Zymeworks Inc | 76.01m | -118.67m | 603.36m | 272.00 | -- | 1.30 | -- | 7.94 | -1.74 | -1.74 | 1.10 | 6.57 | 0.1236 | -- | 2.88 | 279,455.90 | -19.30 | -22.58 | -22.01 | -26.90 | -- | -- | -156.13 | -91.17 | -- | -- | 0.0003 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Cabaletta Bio Inc | 0.00 | -67.68m | 606.59m | 101.00 | -- | 2.62 | -- | -- | -1.65 | -1.65 | 0.00 | 4.94 | 0.00 | -- | -- | 0.00 | -36.52 | -33.76 | -39.22 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Stoke Therapeutics Inc | 8.78m | -104.70m | 607.69m | 110.00 | -- | 3.36 | -- | 69.21 | -2.38 | -2.38 | 0.1996 | 3.47 | 0.0363 | -- | 26.94 | 79,827.27 | -43.23 | -31.62 | -49.60 | -33.92 | -- | -- | -1,192.34 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Wave Life Sciences Ltd | 113.31m | -57.51m | 612.64m | 266.00 | -- | 15.06 | -- | 5.41 | -0.5397 | -0.5397 | 1.07 | 0.3987 | 0.5378 | -- | -- | 425,958.70 | -27.30 | -56.98 | -70.41 | -102.38 | -- | -- | -50.76 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| SIGA Technologies Inc | 139.92m | 68.07m | 615.65m | 45.00 | 9.21 | 3.13 | 8.96 | 4.40 | 0.9399 | 0.9399 | 1.95 | 2.77 | 0.6227 | 0.3329 | 4.21 | 3,109,272.00 | 30.29 | 22.34 | 36.42 | 27.56 | 87.69 | 88.65 | 48.65 | 41.14 | 3.23 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| ProKidney Corp | 0.00 | -35.47m | 621.52m | 163.00 | -- | -- | -- | -- | -0.5683 | -0.5683 | 0.00 | -18.43 | 0.00 | -- | -- | 0.00 | -28.86 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
| Hillevax Inc | 0.00 | -123.57m | 625.24m | 90.00 | -- | 2.26 | -- | -- | -3.04 | -3.04 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.35 | -- | -39.90 | -- | -- | -- | -- | -- | -- | -- | 0.0868 | -- | -- | -- | 22.68 | -- | -- | -- |
| Cogent Biosciences Inc | 0.00 | -192.41m | 625.31m | 164.00 | -- | 2.85 | -- | -- | -2.40 | -2.40 | 0.00 | 2.99 | 0.00 | -- | -- | 0.00 | -62.65 | -49.53 | -70.07 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Dianthus Therapeutics Inc | 2.83m | -43.56m | 625.71m | 53.00 | -- | 1.87 | -- | 221.41 | -10.77 | -10.77 | 0.4429 | 11.40 | 0.0173 | -- | -- | 53,320.75 | -26.72 | -41.40 | -28.86 | -44.70 | -- | -- | -1,541.22 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
Data as of Apr 24 2024. Currency figures normalised to Cabaletta Bio Inc's reporting currency: US Dollar USD
49.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fred Alger Management LLCas of 31 Dec 2023 | 3.33m | 6.90% |
| Adage Capital Management LPas of 31 Dec 2023 | 3.27m | 6.77% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.67m | 5.54% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.59m | 5.38% |
| Lynx1 Capital Management LPas of 31 Dec 2023 | 2.11m | 4.38% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.04m | 4.23% |
| Perceptive Advisors LLCas of 31 Dec 2023 | 2.00m | 4.15% |
| Holocene Advisors, LPas of 31 Dec 2023 | 1.92m | 3.98% |
| Commodore Capital LPas of 31 Dec 2023 | 1.90m | 3.94% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 1.83m | 3.80% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
